SQI Diagnostics Inc. and AZOVA Inc. announced the signing of an agreement that subject to an approval by the Food & Drug Administration (FDA), will allow AZOVA to sell and distribute SQI's COVID-19 HOME Antibody Test to its customer base of airlines, wholesale clubs, retail pharmacies, grocery chains, US state and international governments, school districts and universities, and consumers where the test is authorized for distribution through AZOVA's online digital health platform. Once an application is submitted and Emergency Use Authorization (EUA) from the FDA is granted, SQI's COVID-19 HOME Antibody Test and Collection Kit is slated to be the most comprehensive consumer test for antibodies to SARS-CoV-2, the virus which causes COVID-19, as well as antibodies generated by the three major COVID-19 vaccines made by Pfizer, Moderna and Johnson & Johnson. SQI's data show that the test is >99% accurate and will be the first test of its kind for the consumer market. The test is designed to detect all three immune responses (IgG, IgA, and IgM) from both protein regions of the SARS-CoV-2 virus; the nucleocapsid and spike regions.